MiNK Therapeutics Files 2024 10-K
Ticker: INKT · Form: 10-K · Filed: Mar 18, 2025 · CIK: 1840229
Sentiment: neutral
Topics: 10-K, biotech, financials
TL;DR
MiNK Therapeutics filed its 2024 10-K, detailing financials and operations for the year ending Dec 31, 2024.
AI Summary
MiNK Therapeutics, Inc. filed its 2024 10-K on March 18, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as AgenTus Therapeutics, Inc. until January 12, 2021, operates in the biological products sector. The filing details its financial performance and business operations for the year.
Why It Matters
This 10-K filing provides investors and stakeholders with a comprehensive overview of MiNK Therapeutics' financial health and strategic direction for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a biotechnology company, MiNK Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 — Fiscal Year (Reporting period for the 10-K)
- 20250318 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Filer of the 10-K
- AgenTus Therapeutics, Inc. (company) — Former name of MiNK Therapeutics
- 2024-12-31 (date) — Fiscal year end
- 20250318 (date) — Filing date
FAQ
What is the primary business of MiNK Therapeutics, Inc.?
MiNK Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
When did MiNK Therapeutics, Inc. change its name?
The company changed its name from AgenTus Therapeutics, Inc. on January 12, 2021.
What period does this 10-K filing cover?
This 10-K filing covers the fiscal year ending December 31, 2024.
What is the SEC file number for MiNK Therapeutics, Inc.?
The SEC file number for MiNK Therapeutics, Inc. is 001-40908.
Where is MiNK Therapeutics, Inc. headquartered?
MiNK Therapeutics, Inc. is located at 149 Fifth Avenue, Suite 500, New York, NY 10010.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 18, 2025 regarding MiNK Therapeutics, Inc. (INKT).